868697-78-3

Basic information

• Product Name: 2-(3,4-DICHLOROPHENYL)ACETAMIDE
• Synonyms: 2-(3,4-DICHLOROPHENYL)ACETAMIDE
• CAS NO: 868697-78-3
• Molecular Formula: C₈H₇Cl₂NO
• Molecular Weight: 204.06
• Mol File: 868697-78-3.mol

Chemical Properties

• Boiling Point: 376.5±32.0 °C(Predicted)
• Appearance: /
• Density: 1.388±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 15.83±0.40(Predicted)
• CAS DataBase Reference: 2-(3,4-DICHLOROPHENYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,4-DICHLOROPHENYL)ACETAMIDE(868697-78-3)
• EPA Substance Registry System: 2-(3,4-DICHLOROPHENYL)ACETAMIDE(868697-78-3)

Safety Data

• Hazardous Substances Data: 868697-78-3(Hazardous Substances Data)

Usage

Structure

A derivative of acetamide with two chlorine atoms attached to the phenyl ring

Usage

Has been used in pharmaceutical research as a potential antibacterial and antifungal agent

Molecular structure

Suggests potential effectiveness in targeting specific biological pathways or processes, making it a candidate for drug development

Safety

Should be handled and used with care, following proper safety protocols and guidelines

Further research

Needed to fully understand its potential applications and effects.

Upstream product

• 6831-55-6 2-(3,4-dichlorophenyl)acetyl chloride 
• 93467-56-2 2-(3',4'-dichlorophenyl)acetaldehyde 
• 5807-30-7 3,4-dichlorophenyl acetic acid 

Downstream Products

• 165597-75-1 2-(3,4-dichlorophenyl)ethanethioamide 
• 868697-80-7 C₁₀H₄Cl₃NO₂ 
• 868697-79-4 C₁₀H₅Cl₂NO₃ 

Relevant articles and documents

Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor

Fibroblast activation protein (FAP) belongs to the family of prolyl-specific serine proteases and displays both exopeptidase and endopeptidase activities. FAP expression is undetectable in most normal adult tissues, but is greatly upregulated in sites of tissue remodeling, which include fibrosis, inflammation and cancer. Due to its restricted expression pattern and dual enzymatic activities, FAP inhibition is investigated as a therapeutic option for several diseases. In the present study, we described the structure–activity relationship of several synthesized compounds against DPPIV and prolyl oligopeptidase (PREP). In particular, BR102910 (compound 24) showed nanomolar potency and high selectivity. Moreover, the in vivo FAP inhibition study of BR102910 (compound 24) using C57BL/6J mice demonstrated exceptional profiles and satisfactory FAP inhibition efficacy. Based on excellent in vitro and in vivo profiles, the potential of BR102910 (compound 24) as a lead candidate for the treatment of type 2 diabetes is considered.

Ti-superoxide catalyzed oxidative amidation of aldehydes with saccharin as nitrogen source: Synthesis of primary amides

A new heterogeneous catalytic system (Ti-superoxide/saccharin/TBHP) has been developed that efficiently catalyzes oxidative amidation of aldehydes to produce various primary amides. The protocol employs saccharin as amine source and was found to tolerate a wide range of substrates with different functional groups. Moderate to excellent yields, catalyst reusability and operational simplicity are the main highlights. A possible mechanism and the role of the catalyst in oxidative amidation have also been discussed.

3,4-DISUBSTITUTED MALEIMIDES FOR USE AS VASCULAR DAMAGING AGENTS

This invention relates to novel compounds of Formula (I) for use as vascular damaging agents: Formula (I) wherein Rl, R7, R8, R9, ARI, AR2, AR3, p, q and r are as described in the specification. The invention also relates to methods for preparing compounds of Formula (I), to their use as medicaments (including methods for the treatment of angiogenesis or disease states associated with angiogenesis) and to pharmaceutical compositions containing compounds of Formula (I).